第七届海德堡骨髓瘤研讨会会议报告：今日与明日。
Meeting report of the 7th Heidelberg Myeloma Workshop: today and tomorrow.
机构信息
Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.
Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center, Heidelberg, Germany.
出版信息
J Cancer Res Clin Oncol. 2019 Oct;145(10):2445-2455. doi: 10.1007/s00432-019-02998-w. Epub 2019 Aug 12.
PURPOSE
The 7th Heidelberg Myeloma Workshop was held on April 5th and 6th, 2019 at the University Hospital Heidelberg.
METHODS AND RESULTS
Main topics of the meeting were (1) diagnostics and prognostic factors, (2) role of immunotherapy in multiple myeloma (MM), (3) current therapy of MM, (4) biology and genomics of MM as well as (5) novel treatment concepts. A debate on the status of minimal residual disease (MRD) driven therapy was held.
CONCLUSION
Diagnostics and treatment of newly diagnosed and relapsed MM are continuously evolving. While advances in the field of (single cell) genetic analysis now allow for characterization of the disease at an unprecedented resolution, immunotherapeutic approaches and MRD testing are at the forefront of the current clinical trial landscape.
目的
第 7 届海德堡骨髓瘤研讨会于 2019 年 4 月 5 日和 6 日在海德堡大学医院举行。
方法和结果
会议的主要议题包括（1）诊断和预后因素，（2）免疫疗法在多发性骨髓瘤（MM）中的作用，（3）MM 的当前治疗，（4）MM 的生物学和基因组学以及（5）新的治疗概念。就微小残留病（MRD）驱动治疗的现状进行了辩论。
结论
新诊断和复发性 MM 的诊断和治疗在不断发展。虽然（单细胞）遗传分析领域的进展现在可以以前所未有的分辨率对疾病进行特征描述，但免疫治疗方法和 MRD 检测处于当前临床试验领域的前沿。
Zotero 插件